Bundibugyo Ebola tops 1,100 cases as clinical trials near

Scientists trying to develop vaccines and treatments for the fast-growing Bundibugyo Ebola outbreak in Central Africa are running into a basic problem: too little is known about the strain, and the response is being shaped by delayed detection, limited diagnostics and a lack of approved countermeasures.afro.who+2

The outbreak, declared in the Democratic Republic of the Congo on May 15 and later linked to cases in Uganda, has become the largest recorded Bundibugyo outbreak to date. WHO said the epidemic had likely been spreading for weeks before confirmation, and the agency has tied part of the jump in case counts to backlogged samples being tested as lab capacity expands.reuters+4

Tests built for another Ebola strain

A central obstacle has been diagnosis. WHO says early Ebola symptoms are non-specific, making laboratory confirmation essential, while experts told Reuters that many standard tests were designed around the better-known Zaire strain rather than Bundibugyo. WHO and partners have since expanded field testing in eastern Congo, with decentralized devices cutting turnaround times to under an hour in some areas.Item+4

Researchers are also finding that this outbreak may not look like older public perceptions of Ebola. Reuters, citing WHO and data presented by scientists from Congo’s National Institute for Biomedical Research, reported that only 10% of 505 confirmed cases studied showed bleeding symptoms, a reminder that haemorrhage is not a defining feature in every patient.reuters+2

No licensed vaccine, trials set to begin

There is still no licensed vaccine or approved treatment specifically for Bundibugyo virus disease, according to WHO, CDC and Gavi. WHO’s therapeutics advisers have prioritized MBP-134, maftivimab and remdesivir for clinical trials, including possible combination therapy.hhi.harvard+5

WHO Director-General Tedros Adhanom Ghebreyesus said this week that preparations were complete for a trial in Congo expected to start next week, testing remdesivir and MBP-134 alone or together.statnews+2

On June 24, UNICEF and Gavi launched a Request for Expression of Interest aimed at speeding vaccine development and manufacturing readiness, building on Gavi funding earmarked to help bring promising Bundibugyo shots closer to deployment if they prove effective.gavi+2

Outbreak still centered in eastern Congo

The outbreak remains concentrated in eastern Congo, though Uganda has reported imported cases and limited secondary transmission. WHO assessed the risk as very high in Congo, high in Uganda and low globally.ecdc.europa+2

For now, health agencies say the response still depends less on breakthrough medicines than on fundamentals: faster testing, isolation, contact tracing, safe burials and community trust.Item+2